Literature DB >> 25892658

The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients.

Stephen Bruehl1, John W Burns2, Steven D Passik3, Rajnish Gupta4, Asokumar Buvanendran5, Melissa Chont4, Erik Schuster2, Daria Orlowska2, Christopher R France6.   

Abstract

UNLABELLED: The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) predicts increased risk of opioid misuse in chronic pain patients. We evaluated whether higher SOAPP-R scores are associated with greater opioid reinforcing properties, potentially contributing to their predictive utility. Across 2 counterbalanced laboratory sessions, 55 chronic low back pain sufferers completed the SOAPP-R at baseline and measures of back pain intensity, evoked pain responsiveness (thermal, ischemic), and subjective opioid effects after receiving intravenous morphine (.08 mg/kg) or saline placebo. Morphine effect measures were derived for all outcomes, reflecting the difference between morphine and placebo condition values. Higher SOAPP-R scores were significantly associated with greater desire to take morphine again, less feeling down and feeling bad, and greater reductions in sensory low back pain intensity following morphine administration. This latter effect was due primarily to SOAPP-R content assessing medication-specific attitudes and behavior. Individuals exceeding the clinical cutoff (18 or higher) on the SOAPP-R exhibited significantly greater morphine liking, desire to take morphine again, and feeling sedated; less feeling bad; and greater reductions in sensory low back pain following morphine. The SOAPP-R may predict elevated opioid risk in part by tapping into individual differences in opioid reinforcing effects. PERSPECTIVE: Based on placebo-controlled morphine responses, associations were observed between higher scores on a common opioid risk screener (SOAPP-R) and greater desire to take morphine again, fewer negative subjective morphine effects, and greater analgesia. Opioids may provide the best analgesia in those patients at greatest risk of opioid misuse.
Copyright © 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid; abuse risk; analgesia; chronic pain; misuse; personalized medicine; screening

Mesh:

Substances:

Year:  2015        PMID: 25892658      PMCID: PMC4486517          DOI: 10.1016/j.jpain.2015.04.001

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  49 in total

1.  Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial.

Authors:  Robert N Jamison; Edgar L Ross; Edward Michna; Li Q Chen; Caroline Holcomb; Ajay D Wasan
Journal:  Pain       Date:  2010-03-23       Impact factor: 6.961

2.  Pseudoaddiction revisited: a commentary on clinical and historical considerations.

Authors:  Steven D Passik; Kenneth L Kirsh; Lynn Webster
Journal:  Pain Manag       Date:  2011-05

3.  Opioid pseudoaddiction--an iatrogenic syndrome.

Authors:  D E Weissman; J D Haddox
Journal:  Pain       Date:  1989-03       Impact factor: 6.961

4.  Multifactorial preoperative predictors for postcesarean section pain and analgesic requirement.

Authors:  Peter H Pan; Robert Coghill; Timothy T Houle; Melvin H Seid; W Michael Lindel; R Lamar Parker; Scott A Washburn; Lynne Harris; James C Eisenach
Journal:  Anesthesiology       Date:  2006-03       Impact factor: 7.892

5.  Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.

Authors:  James P Zacny; Sandra Gutierrez; Shahla A Bolbolan
Journal:  Drug Alcohol Depend       Date:  2005-01-12       Impact factor: 4.492

6.  Sex-related psychological predictors of baseline pain perception and analgesic responses to pentazocine.

Authors:  Roger B Fillingim; Barbara A Hastie; Timothy J Ness; Toni L Glover; Claudia M Campbell; Roland Staud
Journal:  Biol Psychol       Date:  2004-12-25       Impact factor: 3.251

7.  Gender differences in risk factors for aberrant prescription opioid use.

Authors:  Robert N Jamison; Stephen F Butler; Simon H Budman; Robert R Edwards; Ajay D Wasan
Journal:  J Pain       Date:  2009-11-27       Impact factor: 5.820

8.  Baroreflex sensitivity associated hypoalgesia in healthy states is altered by chronic pain.

Authors:  Ok Y Chung; Stephen Bruehl; Laura Diedrich; André Diedrich; Melissa Chont; David Robertson
Journal:  Pain       Date:  2007-12-31       Impact factor: 6.961

9.  Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.

Authors:  Margaret A Caudill-Slosberg; Lisa M Schwartz; Steven Woloshin
Journal:  Pain       Date:  2004-06       Impact factor: 6.961

10.  Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.

Authors:  Steven D Passik; Arvind Narayana; Ronghua Yang
Journal:  Pain Med       Date:  2014-03-25       Impact factor: 3.750

View more
  7 in total

Review 1.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

2.  Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

Authors:  Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  Addict Biol       Date:  2018-10-08       Impact factor: 4.280

3.  Psychosocial factors predict opioid analgesia through endogenous opioid function.

Authors:  John W Burns; Stephen Bruehl; Christopher R France; Erik Schuster; Daria Orlowska; Asokumar Buvanendran; Melissa Chont; Rajnish K Gupta
Journal:  Pain       Date:  2017-03       Impact factor: 7.926

4.  The association between endogenous opioid function and morphine responsiveness: a moderating role for endocannabinoids.

Authors:  Stephen Bruehl; John W Burns; Amanda Morgan; Kelli Koltyn; Rajnish Gupta; Asokumar Buvanendran; David Edwards; Melissa Chont; Philip J Kingsley; Larry Marnett; Amanda Stone; Sachin Patel
Journal:  Pain       Date:  2019-03       Impact factor: 7.926

Review 5.  Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings.

Authors:  Lynn M Oswald; Kelly E Dunn; David A Seminowicz; Carla L Storr
Journal:  J Pers Med       Date:  2021-04-19

6.  Greater Conditioned Pain Modulation Is Associated With Enhanced Morphine Analgesia in Healthy Individuals and Patients With Chronic Low Back Pain.

Authors:  Stephen Bruehl; Christopher R France; Amanda L Stone; Rajnish Gupta; Asokumar Buvanendran; Melissa Chont; John W Burns
Journal:  Clin J Pain       Date:  2021-01       Impact factor: 3.423

7.  Influence of opioid-related side effects on disability, mood, and opioid misuse risk among patients with chronic pain in primary care.

Authors:  Robert N Jamison; Kathleen Dorado; Anna Mei; Robert R Edwards; Marc O Martel
Journal:  Pain Rep       Date:  2017-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.